Genome-Wide 5-Methylcytosine and 5-Hydroxymethylcytosine Signatures Analysis of Plasma Cell-Free DNA in Schizophrenia

Abstract

Schizophrenia (SCZ) is a highly heritable neuropsychiatric disorder that affects ∼1% of people globally. Despite extensive research, there remains a lack of biomarkers for SCZ diagnosis and disease pathogenesis delineation. Cell-free DNA (cfDNA), which carries the genetic and epigenetic signatures of origin tissue cells, may provide a noninvasive method for biomarker discovery. We performed cfDNA 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) sequencing of plasma samples from 66 individuals with SCZ and 77 healthy controls. We identified 954 differentially 5mC methylated regions (DMRs) and 1474 differentially 5hmC hydroxymethylated regions (DhMRs) that showed distinct patterns between SCZ and control samples. Many DMRs and DhMRs were associated with genes specifically expressed in brain tissues and were enriched in neuronal functions, as well as were enriched for genome-wide association study (GWAS) of psychiatric and brain volume traits. Additionally, colocalization analysis revealed that DhMRs but not DMRs locations significantly overlapped with GWAS-identified genomic loci of SCZ. Moreover, we observed associations between DMRs and DhMRs with brain regional measurements depicted by magnetic resonance imaging. Together, our findings indicated that cfDNA 5mC and 5hmC patterns are accessible epigenomic signatures that can serve as potential biomarkers and to help delineate SCZ pathogenesis.

Keywords

schizophrenia / cell-free DNA / 5-methylcytosine / 5-hydroxymethylcytosine / magnetic resonance imaging

References

[1] R. S. Kahn, I. E. Sommer, R. M. Murray, et al., “Schizophrenia,” Nature Reviews Disease Primers 1 (2015): 15067.

[2] D. Rodrigues-Amorim, T. Rivera-Baltanás, M. López, C. Spuch, J. M. Olivares, R. C. Agís-Balboa, “Schizophrenia: A Review of Potential Biomarkers,” Journal of Psychiatric Research 93 (2017): 37-49.

[3] So Much More to Know. Science 2005; 309(5731): 78-102.

[4] A. F. Pardiñas, P. Holmans, A. J. Pocklington, et al., “Common Schizophrenia Alleles Are Enriched in Mutation-intolerant Genes and in Regions Under Strong Background Selection,” Nature Genetics 50, no. 3 (2018): 381-389.

[5] V. Trubetskoy, A. F. Pardiñas, T. Qi, et al., “Mapping Genomic Loci Implicates Genes and Synaptic Biology in Schizophrenia,” Nature 604, no. 7906 (2022): 502-508.

[6] N. Schrode, S.-M. Ho, K. Yamamuro, et al., “Synergistic Effects of Common Schizophrenia Risk Variants,” Nature Genetics 51, no. 10 (2019): 1475-1485.

[7] M. Tsuang, “Schizophrenia: Genes and Environment,” Biological Psychiatry 47, no. 3 (2000): 210-220.

[8] R. L. Jirtle, M. K. Skinner, “Environmental Epigenomics and Disease Susceptibility,” Nature Reviews Genetics 8, no. 4 (2007): 253-262.

[9] B. C. McKinney, L. L. McClain, C. M. Hensler, et al., “Schizophrenia-associated Differential DNA Methylation in Brain Is Distributed Across the Genome and Annotated to MAD1L1, a Locus at Which DNA Methylation and Transcription Phenotypes Share Genetic Variation With Schizophrenia Risk,” Translational Psychiatry 12, no. 1 (2022): 340.

[10] L. F. Wockner, E. P. Noble, B. R. Lawford, et al., “Genome-wide DNA Methylation Analysis of human Brain Tissue From Schizophrenia Patients,” Translational Psychiatry 4, no. 1 (2014): e339.

[11] P. M. KA, N. J. Eagles, R. Wilton, et al., “Genome-wide Sequencing-based Identification of Methylation Quantitative Trait Loci and Their Role in schizophrenia Risk,” Nature Communications 12, no. 1 (2021): 5251.

[12] M. Tahiliani, K. P. Koh, Y. Shen, et al., “Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1,” Science (New York, NY) 324, no. 5929 (2009): 930-935.

[13] S. Kriaucionis, N. Heintz, “The Nuclear DNA Base 5-hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain,” Science (New York, NY) 324, no. 5929 (2009): 929-930.

[14] H. Spiers, E. Hannon, L. C. Schalkwyk, N. J. Bray, J. Mill, “5-hydroxymethylcytosine Is Highly Dynamic Across human Fetal Brain Development,” BMC Genomics [Electronic Resource] 18, no. 1 (2017): 738.

[15] E. Dong, S. G. Dzitoyeva, F. Matrisciano, P. Tueting, D. R. Grayson, A. Guidotti, “Brain-derived Neurotrophic Factor Epigenetic Modifications Associated With Schizophrenia-Like Phenotype Induced by Prenatal Stress in Mice,” Biological Psychiatry 77, no. 6 (2015): 589-596.

[16] Y. Cheng, Z. Li, S. Manupipatpong, et al., “5-Hydroxymethylcytosine Alterations in the human Postmortem Brains of Autism Spectrum Disorder,” Human Molecular Genetics 27, no. 17 (2018): 2955-2964.

[17] E. Walton, J. Hass, J. Liu, et al., “Correspondence of DNA Methylation between Blood and Brain Tissue and Its Application to Schizophrenia Research,” Schizophrenia Bulletin 42, no. 2 (2016): 406-414.

[18] M. Li, Y. Li, H. Qin, et al., “Genome-wide DNA Methylation Analysis of Peripheral Blood Cells Derived From Patients With First-episode Schizophrenia in the Chinese Han Population,” Molecular Psychiatry 26, no. 8 (2021): 4475-4485.

[19] K. Sun, P. Jiang, K. C. A. Chan, et al., “Plasma DNA Tissue Mapping by Genome-wide Methylation Sequencing for Noninvasive Prenatal, Cancer, and Transplantation Assessments,” Proceedings of the National Academy of Sciences of the United States of America 112, no. 40 (2015): E5503-5512.

[20] J. Moss, J. Magenheim, D. Neiman, et al., “Comprehensive human Cell-type Methylation Atlas Reveals Origins of Circulating Cell-free DNA in Health and Disease,” Nature Communications 9, no. 1 (2018): 5068.

[21] J. Jiang, X. Chen, L. Sun, et al., “Analysis of the Concentrations and Size Distributions of Cell-free DNA in Schizophrenia Using Fluorescence Correlation Spectroscopy,” Translational Psychiatry 8, no. 1 (2018): 104.

[22] A. Lubotzky, I. Pelov, R. Teplitz, et al., “Elevated Brain-derived Cell-free DNA Among Patients With First Psychotic Episode—a Proof-of-concept Study,” Elife 11 (2022): e76391.

[23] P. Song, L. R. Wu, Y. H. Yan, et al., “Limitations and Opportunities of Technologies for the Analysis of Cell-free DNA in Cancer Diagnostics,” Nature Biomedical Engineering 6, no. 3 (2022): 232-245.

[24] S. Y. Shen, R. Singhania, G. Fehringer, et al., “Sensitive Tumour Detection and Classification Using Plasma Cell-free DNA Methylomes,” Nature 563, no. 7732 (2018): 579-583.

[25] C.-X. Song, S. Yin, L. Ma, et al., “5-Hydroxymethylcytosine Signatures in Cell-free DNA Provide Information About Tumor Types and Stages,” Cell Research 27, no. 10 (2017): 1231-1242.

[26] Y. Zhao, Q. Zhang, C. Shah, et al., “Cortical Thickness Abnormalities at Different Stages of the Illness Course in Schizophrenia: A Systematic Review and Meta-analysis,” JAMA Psychiatry 79, no. 6 (2022): 560-570.

[27] W. Zhang, W. Deng, L. Yao, et al., “Brain Structural Abnormalities in a Group of Never-Medicated Patients with Long-Term Schizophrenia,” The American Journal of Psychiatry 172, no. 10 (2015): 995-1003.

[28] T. G. M. van Erp, D. P. Hibar, J. M. Rasmussen, et al., “Subcortical Brain Volume Abnormalities in 2028 Individuals With Schizophrenia and 2540 Healthy Controls via the ENIGMA Consortium,” Molecular Psychiatry 21, no. 4 (2016): 547-553.

[29] Q. Zhao, H. Cao, W. Zhang, et al., “A Subtype of Institutionalized Patients With Schizophrenia Characterized by Pronounced Subcortical and Cognitive Deficits,” Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 47, no. 12 (2022): 2024-2032.

[30] P. A. Geoffroy, B. Etain, J. Houenou, “Gene X Environment Interactions in Schizophrenia and Bipolar Disorder: Evidence From Neuroimaging,” Frontiers in Psychiatry 4 (2013): 136.

[31] N. E. M. van Haren, M. M. Picchioni, C. McDonald, et al., “A Controlled Study of Brain Structure in Monozygotic Twins Concordant and Discordant for Schizophrenia,” Biological Psychiatry 56, no. 6 (2004): 454-461.

[32] R. L. Suddath, G. W. Christison, E. F. Torrey, M. F. Casanova, D. R. Weinberger, “Anatomical Abnormalities in the Brains of Monozygotic Twins Discordant for Schizophrenia,” The New England Journal of Medicine 322, no. 12 (1990): 789-794.

[33] J. Liu, P. Siyahhan Julnes, J. Chen, S. Ehrlich, E. Walton, V. D. Calhoun, “The Association of DNA Methylation and Brain Volume in Healthy Individuals and Schizophrenia Patients,” Schizophrenia Research 169, no. 1-3 (2015): 447-452.

[34] E. Heitzer, L. Auinger, M. R. Speicher, “Cell-Free DNA and Apoptosis: How Dead Cells Inform about the Living,” Trends in Molecular Medicine 26, no. 5 (2020): 519-528.

[35] A. E. Jaffe, Y. Gao, A. Deep-Soboslay, et al., “Mapping DNA Methylation Across Development, Genotype and Schizophrenia in the human Frontal Cortex,” Nature Neuroscience 19, no. 1 (2016): 40-47.

[36] R. Birnbaum, D. R. Weinberger, “Genetic Insights Into the Neurodevelopmental Origins of Schizophrenia,” Nature Reviews Neuroscience 18, no. 12 (2017): 727-740.

[37] T. Singh, T. Poterba, D. Curtis, et al., “Rare Coding Variants in Ten Genes Confer Substantial Risk for Schizophrenia,” Nature 604, no. 7906 (2022): 509-516.

[38] K. Watanabe, E. Taskesen, A. van Bochoven, D. Posthuma, “Functional Mapping and Annotation of Genetic Associations With FUMA,” Nature Communications 8, no. 1 (2017): 1826.

[39] Y. Nawa, H. Kimura, D. Mori, et al., “Rare Single-nucleotide DAB1 Variants and Their Contribution to Schizophrenia and Autism Spectrum Disorder Susceptibility,” Human Genome Variation 7, no. 1 (2020): 37.

[40] H. Imai, H. Shoji, M. Ogata, et al., “Dorsal Forebrain-Specific Deficiency of Reelin-Dab1 Signal Causes Behavioral Abnormalities Related to Psychiatric Disorders,” Cerebral Cortex (New York, NY: 1991) 27, no. 7 (2017): 3485-3501.

[41] Z. He, K. C. Wang, V. Koprivica, G. Ming, H.-J. Song, “Knowing How to Navigate: Mechanisms of Semaphorin Signaling in the Nervous System,” Science's STKE: Signal Transduction Knowledge Environment 2002, no. 119 (2002): re1.

[42] S. L. Eastwood, A. J. Law, I. P. Everall, P. J. Harrison, “The Axonal Chemorepellant Semaphorin 3A Is Increased in the Cerebellum in Schizophrenia and May Contribute to Its Synaptic Pathology,” Molecular Psychiatry 8, no. 2 (2003): 148-155.

[43] N. Loyfer, J. Magenheim, A. Peretz, et al., “A DNA Methylation Atlas of Normal human Cell Types,” Nature 613, no. 7943 (2023): 355-364.

[44] B. He, C. Zhang, X. Zhang, et al., “Tissue-specific 5-hydroxymethylcytosine Landscape of the human Genome,” Nature Communications 12, no. 1 (2021): 4249.

[45] W. B. Ruzicka, S. Subburaju, F. M. Benes, “Variability of DNA Methylation Within Schizophrenia Risk Loci Across Subregions of Human Hippocampus,” Genes 8, no. 5 (2017): 143.

[46] O. D. Howes, B. R. Bukala, K. Beck, “Schizophrenia: From Neurochemistry to Circuits, Symptoms and Treatments,” Nature Reviews Neurology 20, no. 1 (2024): 22-35.

[47] M. A. Niznikiewicz, “Neurobiological Approaches to the Study of Clinical and Genetic High Risk for Developing Psychosis,” Psychiatry Research 277 (2019): 17-22.

[48] V. L. Cropley, M. Fujita, R. B. Innis, P. J. Nathan, “Molecular Imaging of the Dopaminergic System and Its Association With human Cognitive Function,” Biological Psychiatry 59, no. 10 (2006): 898-907.

[49] M. Kirschner, B. Hodzic-Santor, M. Antoniades, et al., “Cortical and Subcortical Neuroanatomical Signatures of Schizotypy in 3004 Individuals Assessed in a Worldwide ENIGMA Study,” Molecular Psychiatry 27, no. 2 (2022): 1167-1176.

[50] R. Hashimoto, M. Ikeda, F. Yamashita, et al., “Common Variants at 1p36 Are Associated With Superior Frontal Gyrus Volume,” Translational Psychiatry 4, no. 10 (2014): e472.

[51] M. F. Alonso-Sánchez, R. Limongi, J. Gati, L. Palaniyappan, “Language Network Self-inhibition and Semantic Similarity in First-episode Schizophrenia: A Computational-linguistic and Effective Connectivity Approach,” Schizophrenia Research 259 (2023): 97-103.

[52] S. P. Singh, J. E. Cooper, H. L. Fisher, et al., “Determining the Chronology and Components of Psychosis Onset: The Nottingham Onset Schedule (NOS),” Schizophrenia Research 80, no. 1 (2005): 117-130.

[53] D. M. Gardner, A. L. Murphy, H. O'Donnell, F. Centorrino, R. J. Baldessarini, “International Consensus Study of Antipsychotic Dosing,” The American Journal of Psychiatry 167, no. 6 (2010): 686-693.

[54] S. R. Kay, A. Fiszbein, L. A. Opler, “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia,” Schizophrenia Bulletin 13, no. 2 (1987): 261-276.

[55] L.-J. Wang, Y.-C. Huang, C.-F. Hung, et al., “The Chinese Version of the Brief Assessment of Cognition in Schizophrenia: Data of a Large-Scale Mandarin-Speaking Population,” Archives of Clinical Neuropsychology 32, no. 3 (2017): 289-296.

[56] M. Zhao, G. Xue, B. He, et al., “Integrated Multiomics Signatures to Optimize the Accurate Diagnosis of Lung Cancer,” Nature Communications 16, no. 1 (2025): 84.

[57] S. Chen, Y. Zhou, Y. Chen, J. Gu, “fastp: An Ultra-fast All-in-one FASTQ Preprocessor,” Bioinformatics 34, no. 17 (2018): i884-i890.

[58] H. Li, R. Durbin, “Fast and Accurate Short Read Alignment With Burrows-Wheeler Transform,” Bioinformatics 25, no. 14 (2009): 1754-60.

[59] H. Li, B. Handsaker, A. Wysoker, et al., “The Sequence Alignment/Map Format and SAMtools,” Bioinformatics 25, no. 16 (2009): 2078-9.

[60] R. G. Cavalcante, M. A. Sartor, “annotatr: Genomic Regions in Context,” Bioinformatics (Oxford, England) 33, no. 15 (2017): 2381-2383.

[61] J.-X. Yue, G. Liti, “simuG: A General-purpose Genome Simulator,” Bioinformatics (Oxford, England) 35, no. 21 (2019): 4442-4444.

[62] B. Fischl, “FreeSurfer,” Neuroimage 62, no. 2 (2012): 774-781.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.